Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.
ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion ...
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, approved ONAPGO injection, formerly known as ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Supernus ...